The table below shows CRISPR Therapeutics AG's income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Revenue
$3.51M
$37.31M
$371.21M
$1.20M
$914.96M
$719.00K
Cost of revenue
-
-
-
-
-
-
Gross profit
-
-
-
-
-
-
R&D
$284.81M
$310.24M
$387.33M
$461.64M
$340.57M
$221.38M
SG&A
CRSP annual revenue (10-K history)
CRISPR Therapeutics AG reported annual revenue of $3.51M for fiscal year 2025. That is down 90.6% from $37.31M in fiscal 2024. Over the 10 fiscal years shown, annual revenue declined from $5.16M (FY 2016) to $3.51M. Figures come from the company's audited annual reports as filed with the SEC.
